Skip to main content
SpringerLink
Log in

Malignant Tumors

  • Chapter
Clinical Hepatology

  • 1885 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aihara T, Noguchi S, Sasaki Y, et al (1996) Clonal analysis of precancerous lesions of hepatocellular carcinoma. Gastroenterology 111: 455–61

    Article  CAS  PubMed  Google Scholar 

  2. Alj Y, Georgiakaki M, Savouret JF, et al (2004) Hereditary persistence of alpha-fetoprotein is due to both proximal and distal hepatocyte nuclear factor-1 site mutations. Gastroenterology 126: 308–17

    Article  CAS  PubMed  Google Scholar 

  3. Anthony PP, James K (1987) Pedunculated hepatocellular carcinoma. Is it an entity? Histopathology 11: 402–14

    Article  Google Scholar 

  4. Anthony PP, Vogel CL, Barker LF (1973) Liver cell dys-plasia: a premalignant condition. J Clin Pathol 26: 217–23

    Article  CAS  PubMed  Google Scholar 

  5. Baek HJ, Lim SC, Kitisin K, et al (2008) Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48: 1128–37

    Article  CAS  PubMed  Google Scholar 

  6. Beasley RP (1988) Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61: 1942–56

    Article  CAS  PubMed  Google Scholar 

  7. Becker G, Soezgen T, Olschewski M, et al (2005) Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 11: 6104–9

    PubMed  Google Scholar 

  8. Becker G, Allgaier HP, Olschewski M, et al (2007) Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepato-logy 45: 9–15

    Article  CAS  Google Scholar 

  9. Bialecki ES, Ezenekwe AM, Brunt EM, et al (2006) Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 4: 361–8

    Article  PubMed  Google Scholar 

  10. Bismuth H, Majno PE, Adam R (1999) Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 19: 311–22

    Article  CAS  PubMed  Google Scholar 

  11. Blaker M, Schmitz M, Gocht A, et al (2004) Differential expression of somatostatin receptor subtypes in hepatocel-lular carcinomas. J Hepatol 41: 112–8

    Article  CAS  PubMed  Google Scholar 

  12. Blum HE (2007) Schwerpunkt: Leberzellkarzinom. Epidemiologie, Diagnostik und Prävention. Der Gastroen-terologe 2: 6–11

    Article  Google Scholar 

  13. Bolondi L, Sofia S, Siringo S, et al (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251–9

    Article  CAS  PubMed  Google Scholar 

  14. Bolondi L, Gaiani S, Celli N, et al (2005) Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42: 27–34

    Article  PubMed  Google Scholar 

  15. Borzio M, Bruno S, Roncalli M, et al (1995) Liver cell dys-plasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 108: 812–7

    Article  CAS  PubMed  Google Scholar 

  16. Borzio M, Fargion S, Borzio F, et al (2003) Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 39: 208–14

    Article  PubMed  Google Scholar 

  17. Bosch FX, Ribes J, Diaz M, et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: S5–16

    Article  PubMed  Google Scholar 

  18. Bosetti C, Levi F, Boffetta P, et al (2008) Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 48: 137–45

    Article  PubMed  Google Scholar 

  19. Bravi F, Bosetti C, Tavani A, et al (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepa-tology 46: 430–5

    Google Scholar 

  20. Bruix J, Castells A, Calvet X, et al (1990) Diarrhea as a presenting symptom of hepatocellular carcinoma. Dig Dis Sci 35: 681–5

    Article  CAS  PubMed  Google Scholar 

  21. Bruix J, Sherman M, Llovet JM, et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35: 421–30

    Article  CAS  PubMed  Google Scholar 

  22. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208–36

    Article  PubMed  Google Scholar 

  23. Bruno S, Crosignani A, Maisonneuve P, et al (2007) Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46: 1350–6

    Article  CAS  PubMed  Google Scholar 

  24. Burrel M, Llovet JM, Ayuso C, et al (2003) MRI angiogra-phy is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38: 1034–42

    PubMed  Google Scholar 

  25. Byrnes V, Shi H, Kiryu S, et al (2007) The clinical outcome of small (< 20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am J Gastroenterol 102: 1654–9

    Article  PubMed  Google Scholar 

  26. Caldwell SH, Crespo DM, Kang HS, et al (2004) Obesity and hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1): S97–103

    Article  CAS  PubMed  Google Scholar 

  27. Camma C, Di Marco V, Orlando A, et al (2005) Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. J Hepatol 42: 535–40

    Article  PubMed  Google Scholar 

  28. Cantarini MC, de la Monte SM, Pang M, et al (2006) Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 44: 446–57

    Article  CAS  PubMed  Google Scholar 

  29. Cantarini MC, Trevisani F, Morselli-Labate AM, et al (2006) Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 101: 91–8

    Article  PubMed  Google Scholar 

  30. Capocaccia R, Sant M, Berrino F, et al (2007) Hepatocellular Carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 102: 1661–70

    Article  PubMed  Google Scholar 

  31. Capurro M, Wanless IR, Sherman M, et al (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125: 89–97

    Article  CAS  PubMed  Google Scholar 

  32. Chan HL, Hui AY, Wong ML, et al (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53: 1494–8

    Article  PubMed  Google Scholar 

  33. Chan KL, Guan XY, Ng IO (2004) High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 35: 1324–31

    Article  CAS  PubMed  Google Scholar 

  34. Chau GY, Lee AF, Tsay SH, et al (2007) Clinicopathological significance of survivin expression in patients with hepato-cellular carcinoma. Histopathology 51: 204–18

    Article  PubMed  Google Scholar 

  35. Chen CH, Chen YY, Chen GH, et al (2004) Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13,676 relatives with hepatocel-lular carcinoma. J Hepatol 40: 653–9

    Article  PubMed  Google Scholar 

  36. Chen CJ, Liang K Y, Chang AS, et al (1991) Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 13: 398–406

    Article  CAS  PubMed  Google Scholar 

  37. Chen CJ, Chen DS (2002) Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage carcinogenesis with multifactorial etiology. Hepatology 36: 1046–8

    Article  PubMed  Google Scholar 

  38. Chen CJ, Yang HE, Su J, et al (2006) Risk of hepatocellu-lar carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65–73

    Article  CAS  PubMed  Google Scholar 

  39. Chen CL, Yang HI, Yang WS, et al (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135: 111–21

    Article  CAS  PubMed  Google Scholar 

  40. Chignard N, Shang S, Wang H, et al (2006) Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: detection of generated fragments in patient sera. Gastro enterology 130: 2010–22

    Article  CAS  Google Scholar 

  41. Cillo U, Bassanello M, Vitale A, et al (2004) The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 40: 124–31

    Article  PubMed  Google Scholar 

  42. Cillo U, Vitale A, Grigoletto F, et al (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44: 723–31

    Article  PubMed  Google Scholar 

  43. Colli A, Fraquelli M, Casazza G, et al (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101: 513–23

    Article  CAS  PubMed  Google Scholar 

  44. Collier J, Sherman M (1998) Screening for hepatocellular carcinoma. Hepatology 27: 273–8

    Article  CAS  PubMed  Google Scholar 

  45. Colombo M, de Franchis R, Del Ninno E, et al (1991) Hepa tocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325: 675–80

    Article  CAS  PubMed  Google Scholar 

  46. Conti JA, Kemeny N (1992) Type Ia glycogenosis associated with hepatocellular carcinoma. Cancer 69: 1320–2

    Article  CAS  PubMed  Google Scholar 

  47. Daniele B, Perrone F (2005) Staging for liver cancer. Clin Liver Dis 9: 213–23

    Article  PubMed  Google Scholar 

  48. Davila JA, Morgan RO, Shaib Y, et al (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54: 533–9

    Article  CAS  PubMed  Google Scholar 

  49. Davila JA, El-Serag HB (2006) Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 4: 104–10

    Article  PubMed  Google Scholar 

  50. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al (2006) Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12: 1761–9

    Article  PubMed  Google Scholar 

  51. Demo E, Frush D, Gottfried M, et al (2007) Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol 46: 492–8

    Article  CAS  PubMed  Google Scholar 

  52. D'Errico A, Baccarini P, Fiorentino M, et al (1996) Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and mRNA detection. Hum Pathol 27: 599–604

    Article  PubMed  Google Scholar 

  53. Deugnier YM, Charalamous P, Le Quilleuc D, et al (1993) Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 18: 1363–9

    CAS  PubMed  Google Scholar 

  54. Deugnier YM, Guyader D, Crantock L, et al (1993) Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 104: 228–34

    CAS  PubMed  Google Scholar 

  55. Di Bisceglie AM, Strasberg S (2004) A common staging system for hepatocellular carcinoma. Hepatology 39: 550–1

    Article  Google Scholar 

  56. Di Tommaso L, Franchi G, Park YN, et al (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45: 725–34

    Article  PubMed  CAS  Google Scholar 

  57. Ebara M, Okabe S, Kita K, et al (2005) Percutaneous etha-nol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43: 458–64

    Article  CAS  PubMed  Google Scholar 

  58. Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver. A study of 100 cases among 48900 necropsies. Cancer 7: 462–503

    Article  CAS  PubMed  Google Scholar 

  59. Eggel H (1901) Über das primäre Karzinom der Leber. Beitr Pathol Anat Allg Pathol 30: 506–604

    Google Scholar 

  60. El-Serag HB, Mason AC (1999) Rising incidence of hepa-tocellular carcinoma in the United States. N Engl J Med 340: 745–50

    Article  CAS  PubMed  Google Scholar 

  61. El-Serag HB (2001) Epidemiology of hepatocellular carcinoma. Clin Liv Dis 5: 87–107

    Article  CAS  Google Scholar 

  62. El-Serag HB, Mason AC, Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33: 62–5

    Article  CAS  PubMed  Google Scholar 

  63. El-Serag HB, Richardson PA, Everhart JE (2001) The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroeneterol 96: 2462–7

    Article  CAS  Google Scholar 

  64. El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460–8

    Article  PubMed  Google Scholar 

  65. El-Serag HB, Mallat DB, Rabeneck L (2005) Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Clin Gastroenterol 39: 152–9

    PubMed  Google Scholar 

  66. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4: 369–80

    Article  PubMed  Google Scholar 

  67. Emile JF, Adam R, Sebagh M, et al (2000) Hepatocellular carcinoma with lymphoid stroma: a tumour with good prognosis after liver transplantation. Histopathology 37: 523–29

    Article  CAS  PubMed  Google Scholar 

  68. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. N Engl J Med 314: 736–9

    Article  CAS  PubMed  Google Scholar 

  69. Fargion S, Fracanzani AL, Piperno A, et al (1994) Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 20: 1426–31

    Article  CAS  PubMed  Google Scholar 

  70. Farinati F, Marino D, De Giorgio M, et al (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101: 524–32

    Article  CAS  PubMed  Google Scholar 

  71. Forner A, Bruix J (2008) Locoregional treatment for hepato-cellular carcinoma: from clinical exploration to robust clinical data, changing standards of care. Hepatology 47: 5–7

    Article  PubMed  Google Scholar 

  72. Forner A, Vilana R, Ayuso C, et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepato-cellular carcinoma. Hepatology 47: 97–104

    Article  PubMed  Google Scholar 

  73. Francanzani AL, Taioli E, Sampietro M, et al (2001) Liver cancer risk is increased in patients with pophyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 35: 498–503

    Article  Google Scholar 

  74. Gaiani S, Celli N, Piscaglia F, et al (2004) Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 41: 421–6

    Article  PubMed  Google Scholar 

  75. Gambarin-Gelwan M, Wolf DC, Shapiro R, et al (2000) Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 95: 1535–8

    Article  CAS  PubMed  Google Scholar 

  76. Gelatti U, Covolo L, Franceschini M, et al (2005) Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 42: 528–34

    Article  CAS  PubMed  Google Scholar 

  77. Gordon SC (2005) Occult viral hepatitis and noncirrhotic hepatocellular carcinoma. Am J Gastroenterol 100: 1754–7

    Article  CAS  PubMed  Google Scholar 

  78. Graziadei IW, Sandmueller H, Waldenberger P, et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9: 557–63

    Article  PubMed  Google Scholar 

  79. Grieco A, Pompili M, Caminiti G, et al (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411–8

    Article  CAS  PubMed  Google Scholar 

  80. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH) (2004) Randomized trial of leuprorelin and flutamide in male patients with hepatocel-lular carcinoma treated with tamoxifen. Hepatology 40: 1361–9

    Article  CAS  Google Scholar 

  81. Guerrero RB, Roberts LR (2005) The role of hepatitis B virus integrations in the pathogenesis of human hepatocel-lular carcinoma. J Hepatol 42: 760–77

    Article  CAS  Google Scholar 

  82. Gupta S, Bent S, Kohlwes J (2003) Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139: 46–50

    CAS  PubMed  Google Scholar 

  83. Hanazaki K, Kajikawa S, Koide N, et al (2001) Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitic C viral infection: univariate and multivariate analysis. Am J Gastroenterol 96: 1243–50

    Article  CAS  PubMed  Google Scholar 

  84. Hassan MM, Hwang LY, Hatten CJ, et al (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36: 1206–13

    Article  CAS  PubMed  Google Scholar 

  85. Hata M, Tokuuye K, Sugahara S, et al (2006) Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer 107: 591–8

    Article  PubMed  Google Scholar 

  86. Ho JWY, Pang RWC, Lau C, et al (2006) Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44: 836–43

    Article  CAS  PubMed  Google Scholar 

  87. Hsu IC, Metcalf RA, Sun T, et al (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature 350: 427–8

    Article  CAS  PubMed  Google Scholar 

  88. Hu G, Tuomilehto J, Pukkala E, et al (2008) Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 48: 129–36

    Article  PubMed  Google Scholar 

  89. Huang YH, Chen CH, Chang TT, et al (2004) The role of transcatheter arterial embolization in patients with resect-able hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int 24: 419–24

    Article  PubMed  Google Scholar 

  90. Huo TI, Wu JC, Lui W Y, et al (2004) Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol 99: 1479–87

    Article  PubMed  Google Scholar 

  91. Huo TI, Huang YH, Lin HC, et al (2006) Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 101: 975–82

    Article  PubMed  Google Scholar 

  92. Huo TI, Lin HC, Hsia C Y, et al (2007) The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 102: 1920–30

    Article  PubMed  Google Scholar 

  93. Hytiroglou P, Theise ND (2006) Telomerase activation in human hepatocarcinogenesis. Am J Gastroenterol 101: 839–41

    Article  CAS  PubMed  Google Scholar 

  94. Ikeda K, Marusawa H, Osaki Y, et al (2007) Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 146: 649–56

    PubMed  Google Scholar 

  95. International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22: 983–93

    Google Scholar 

  96. Ishak KG, Anthony PP, Sobin LH (1994) Histological typing of tumours of the liver, 2nd edn. Springer Verlag, Berin/ Heidelberg/New York

    Google Scholar 

  97. Jang JW, Choi J Y, Bae SH, et al (2004) Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 41: 427–35

    Article  CAS  PubMed  Google Scholar 

  98. Jeng KS, Sheen IS, Tsai YC (2004) Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? Am J Gastroenterol 99: 1503–9

    Article  PubMed  Google Scholar 

  99. Jonas S, Bechstein WO, Steinmüller T, et al (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33: 1080–6

    Article  CAS  PubMed  Google Scholar 

  100. Kanai T, Hirohashi S, Upton M, et al (1987) Pathology of small hepatocellular carcinoma. Cancer 60: 810–9

    Article  CAS  PubMed  Google Scholar 

  101. Kanda M, Tateishi R, Yoshida H, et al (2008) Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 28: 1256–63

    Article  CAS  PubMed  Google Scholar 

  102. Kanmura S, Uto H, Kusumoto K, et al (2007) Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology 45: 948–56

    Article  CAS  PubMed  Google Scholar 

  103. Katoh H, Shibata T, Kokubu A, et al (2005) Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol 43: 863–74

    Article  CAS  PubMed  Google Scholar 

  104. Katoh H, Ojima H, Kokubu A, et al (2007) Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology 133: 1475–86

    Article  CAS  PubMed  Google Scholar 

  105. Kauppinen R, Mustajoki P (1988) Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 57: 117–20

    CAS  PubMed  Google Scholar 

  106. Kekulé AS, Lauer U, Weiss L, et al (1993) Hepatitis B virus transactivator HBX uses a tumour promoter signalling pathway. Nature 361: 742–5

    Article  PubMed  Google Scholar 

  107. Kew MC (2000) Hepatocellular carcinoma. A century of progress. Clin Liv Dis 4: 257–68

    Article  CAS  Google Scholar 

  108. Khan MA, Combs CS, Brunt EM, et al (2000) Positron emission tomography scanning in the evaluation of hepato-cellular carcinoma. J Hepatol 32: 792–7

    Article  CAS  PubMed  Google Scholar 

  109. Khan KN, Yatsuhashi H, Yamasaki K, et al (2000) Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 32: 269–78

    Article  CAS  PubMed  Google Scholar 

  110. Kim H, Park C, Han KH, et al (2004) Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) pheno-type. J Hepatol 40: 298–304

    Article  CAS  PubMed  Google Scholar 

  111. Kim JW, Ye Q, Forgues M, et al (2004) Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 39: 518–27

    Article  CAS  PubMed  Google Scholar 

  112. Knisely AS, Strautnieks SS, Meier Y, et al (2006) Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44: 478–86

    Article  CAS  PubMed  Google Scholar 

  113. Kobayashi S, Takeda T, Enomoto M, et al (2007) Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1,124 patients. Liver Int 27: 186–91

    Article  CAS  PubMed  Google Scholar 

  114. Koda M, Murawaki Y, Mitsuda A, et al (2000) Predictive factors for intrahepatic recurrence after percutaneous etha-nol injection therapy for small hepatocellular carcinoma. Cancer 88: 529–37

    Article  CAS  PubMed  Google Scholar 

  115. Kojiro M, Nakashima O (1999) Histopathologic evolution of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 19: 287–96

    Article  CAS  PubMed  Google Scholar 

  116. Komura T, Mizukoshi E, Kita Y, et al (2007) Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 102: 1939–46

    Article  CAS  PubMed  Google Scholar 

  117. Kong S Y, Park JW, Lee JA, et al (2007) Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 46: 446–55

    Article  CAS  PubMed  Google Scholar 

  118. Kouroumalis E, Skordilis P, Thermos K, et al (1998) Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 42: 442–7

    Article  CAS  PubMed  Google Scholar 

  119. Kudo M, Chung H, Haji S, et al (2004) Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40: 1396–1405

    Article  PubMed  Google Scholar 

  120. Kulik LM, Carr BI, Mulcahy MF, et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47: 71–81

    Article  PubMed  Google Scholar 

  121. Kurogi M, Nakashima O, Miyaaki H, et al (2006) Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol 21: 1470–7

    PubMed  Google Scholar 

  122. Kurokawa Y, Matoba R, Takemasa I, et al (2004) Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 41: 284–91

    Article  CAS  PubMed  Google Scholar 

  123. Lai MS, Hsieh MS, Chiu YH, et al (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295–302

    Article  PubMed  Google Scholar 

  124. Larsson SC, Wolk A (2007) Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 132: 1740–5

    Article  PubMed  Google Scholar 

  125. Lee JS, Chu IS, Heo J, et al (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–76

    Article  CAS  PubMed  Google Scholar 

  126. Lencioni R, Allgaier HP, Cioni D, et al (2003) Small hepa-tocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus ethanol injection. Radiology 228: 235–40

    Article  PubMed  Google Scholar 

  127. Lencioni R, Crocetti L, Petruzzi P, et al (2008) Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepato-cellular carcinoma: a pilot clinical study. J Hepatol 49: 217–22

    Article  CAS  PubMed  Google Scholar 

  128. Lencioni R, Piscaglia F, Bolondi L (2008) Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 48: 848–57

    Article  PubMed  Google Scholar 

  129. Leong ASY, Sarmunen RT, Tsui MWS, et al (1998) Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocar-cinoma, combined tumours and metastatic carcinoma. Histopathology 33: 318–24

    Article  CAS  PubMed  Google Scholar 

  130. Leung TWT, Patt YZ, Lau WY, et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5: 1676–81

    CAS  PubMed  Google Scholar 

  131. Leung TWT, Tang AMY, Zee B, et al (2002) Construction of the Chinese University prognostic index for hepatocel-lular carcinoma and comparison with the TNM staging system, the Okuda staging system and the Cancer of the Liver Italian Program staging system. Cancer 94: 1760–9

    Article  PubMed  Google Scholar 

  132. Leykum LK, El-Serag HB, Cornell J, et al (2007) Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol 5: 508–12

    Article  PubMed  Google Scholar 

  133. Lian Z, Liu J, Wu M, et al (2007) Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology 45: 1390–9

    Article  CAS  PubMed  Google Scholar 

  134. Libbrecht L, Bielen D, Verslype C, et al (2002) Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 8: 749–61

    Article  PubMed  Google Scholar 

  135. Libbrecht L (2006) Hepatic progenitor cells in human liver tumor development. World J Gastroenterology 12: 6261–5

    Google Scholar 

  136. Libbrecht L, Severi T, Cassiman D, et al (2006) Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 30: 1405–11

    Article  PubMed  Google Scholar 

  137. Liebman HA, Furie BC, Tong MJ, et al (1984) Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310: 1427–31

    Article  CAS  PubMed  Google Scholar 

  138. Lin SM, Lin CJ, Lin CC, et al (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < 4 cm. Gastroenterology 127: 1714–23

    Article  PubMed  Google Scholar 

  139. Lin SM, Lin CJ, Lin CC, et al (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54: 1151–6

    Article  CAS  PubMed  Google Scholar 

  140. Liu XE, Desmyter L, Gao CF, et al (2007) N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46: 1426–35

    Article  CAS  PubMed  Google Scholar 

  141. Livraghi T, Goldberg SN, Lazzaroni S, et al (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655–61

    CAS  PubMed  Google Scholar 

  142. Livraghi T, Meloni F, Di Stasi M, et al (2008) Sustained complete response and complication rates after radiofre-quency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47: 82–9

    Article  PubMed  Google Scholar 

  143. Llovet JM, Bruix J, Fuster J, et al (1998) Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power. Hepatology 27: 15727

    Article  Google Scholar 

  144. Llovet JP, Brú C, Bruix C (1999) Prognosis of hepatocel-lular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329–38

    Article  CAS  PubMed  Google Scholar 

  145. Llovet JM, Bustamante J. Castells A, et al (1999) Prospective followup of untreated hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29: 62–7

    Article  CAS  PubMed  Google Scholar 

  146. Llovet JM, Vilana R, Brú C, et al (2001) Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33: 1124–9

    Article  CAS  PubMed  Google Scholar 

  147. Llovet JM, Real MI, Montana X, et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734–9

    Article  PubMed  Google Scholar 

  148. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429–42

    Article  CAS  PubMed  Google Scholar 

  149. Llovet JM, Chen Y, Wurmbach E, et al (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastro-enterology 131: 1758–67

    Article  CAS  Google Scholar 

  150. Llovet JM, Ricci S, Mazzaferro V, et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–90

    Article  CAS  PubMed  Google Scholar 

  151. Lu DS, Yu NC, Raman SS, et al (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41: 1130–7

    Article  PubMed  Google Scholar 

  152. Maheshwari S, Sarraj A, Kramer J, et al (2007) Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 47: 506–13

    Article  CAS  PubMed  Google Scholar 

  153. Marhenke S, Lamlé J, Buitrago-Molina LE, et al (2008) Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology 48: 487–96

    Article  CAS  PubMed  Google Scholar 

  154. Marrero JA, Fontana RJ, Su GL, et al (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36: 1349–54

    PubMed  Google Scholar 

  155. Marrero JA, Su GL, Wei W, et al (2003) Des-gamma car-boxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37: 1114–21

    Article  CAS  PubMed  Google Scholar 

  156. Marrero JA, Fontana RJ, Barrat A, et al (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707–16

    Article  PubMed  Google Scholar 

  157. Marrero JA, Fontana RJ, Fu S, et al (2005) Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42: 218–24

    Article  CAS  PubMed  Google Scholar 

  158. Martins A, Cortez-Pinto H, Marques-Vidal P, et al (2006) Treatment and prognostic factors in patients with hepato-cellular carcinoma. Liver Int 26: 680–7

    Article  CAS  PubMed  Google Scholar 

  159. Mazzaferro V, Regalia E, Doci R, et al (1996) Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 643–9

    Article  Google Scholar 

  160. Ming L, Thorgeirisson SS, Gail MH, et al (2002) Dominant role of hepatitis B virus and co-factor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36: 1214–20

    Article  CAS  PubMed  Google Scholar 

  161. Murakami Y, Saigo K, Takashima H, et al (2005) Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 4: 1162–8

    Article  CAS  Google Scholar 

  162. Nagai H, Terada Y, Tajiri T, et al (2004) Characterization of liver-cirrhosis nodules by analysis of gene-expression pro-files and patterns of allelic loss. J Hum Genet 49: 246–55

    Article  CAS  PubMed  Google Scholar 

  163. Nagaoka S, Itano S, Ishibashi M, et al (2006) Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 26: 781–8

    Article  PubMed  Google Scholar 

  164. Nagaoka S, Yoshida T, Akiyoshi J, et al (2007) Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 27: 1091–7

    Article  CAS  PubMed  Google Scholar 

  165. Nahon P, Sutton A, Rufat P, et al (2008) Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134: 102–10

    Article  CAS  PubMed  Google Scholar 

  166. Nakamura S, Nouso K, Sakaguchi K, et al (2006) Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101: 2038–43

    Article  CAS  PubMed  Google Scholar 

  167. Nam SW, Park JY, Ramasamy A, et al (2005) Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42: 809–18

    Article  CAS  PubMed  Google Scholar 

  168. Natarajan S, Theise ND, Thung SN, et al (1997) Large-cell change of hepatocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol 21: 312–8

    Article  CAS  PubMed  Google Scholar 

  169. Nguyen MH, Whittemore AS, Garcia RT, et al (2004) Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2: 820–4

    Article  PubMed  Google Scholar 

  170. Niederau C, Fischer R, Sonnenberg A, et al (1985) Survival and causes of death in cirrhotic and non-cirrhotic patients with primary haemochromatosis. N Engl J Med 313: 1256–62

    Article  CAS  PubMed  Google Scholar 

  171. N'Kontchou G, Paries J, Htar MT, et al (2006) Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 4: 1062–8

    Article  PubMed  Google Scholar 

  172. Nomura F, Ishijima M, Kuwa K, et al (1999) Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 94: 650–4

    Article  CAS  PubMed  Google Scholar 

  173. Nowak A, Findlay M, Culjak G, et al (2004) Tamoxifen for hepatocellular carcinoma (Cochrane Review). In: The Cochrane Library, Issue 3. Wiley, Chichester

    Google Scholar 

  174. Oikawa T, Ojima H, Yamasaki S, et al (2005) Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. J Hepatol 42: 225–9

    Article  PubMed  Google Scholar 

  175. Okamura N, Yoshida M, Shibuya A, et al (2005) Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int 55: 724–31

    Article  CAS  PubMed  Google Scholar 

  176. Okuda K, Peters RL, Simson IW (1984) Gross anatomic features of hepatocellular carcinoma from three disparate geographical areas. Proposal of new classification. Cancer 54: 2165–73

    Article  CAS  PubMed  Google Scholar 

  177. Okuda K, Ohtsuki T, Obata H, et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56: 918–28

    Article  CAS  PubMed  Google Scholar 

  178. O'Malley ME, Takayama Y, Sherman M, (2005) Outcome of small (10–20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in patients with cirrhosis or chronic liver disease. Am J Gastroenterol 100: 1523–8

    Article  PubMed  Google Scholar 

  179. Paradis V, Degos F, Dargere D, et al (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41: 40–7

    Article  CAS  PubMed  Google Scholar 

  180. Park IY, Sohn BH, Yu E, et al (2007) Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132: 1476–94

    Article  CAS  PubMed  Google Scholar 

  181. Pascual S, Irurzun J, Zapater P, et al (2008) Usefulness of surveillance programmes for early diagnosis of hepatocel-lular carcinoma in clinical practice. Liver Int 28: 682–9

    Article  PubMed  Google Scholar 

  182. Patel D, Terrault NA, Yao F Y, et al (2005) Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 3: 75–84

    Article  PubMed  Google Scholar 

  183. Plentz RR, Caselitz M, Bleck JS, et al (2004) Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40: 80–6

    Article  CAS  PubMed  Google Scholar 

  184. Plentz RR, Schlegelberger B, Flemming P, et al (2005) Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology 42: 522–6

    Article  CAS  PubMed  Google Scholar 

  185. Plentz RR, Park YN, Lechel A, et al (2007) Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 45: 968–76

    Article  CAS  PubMed  Google Scholar 

  186. Pocobelli G, Cook LS, Brant R, et al (2008) Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 28: 1272–9

    Article  PubMed  Google Scholar 

  187. Pollicino T, Squadrito G, Cerenzia G, et al (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126: 102–10

    Article  CAS  PubMed  Google Scholar 

  188. Pollicino T, Raffa G, Costantino L, et al (2007) Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 45: 277–85

    Article  CAS  PubMed  Google Scholar 

  189. Price JA, Kovach SJ, Johnson T et al (2002) Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology 36: 1089–97

    Article  CAS  PubMed  Google Scholar 

  190. Raidl M, Pirker C, Schulte-Hermann R, et al (2004) Multiple chromosomal abnormalities in human liver (pre) neoplasia. J Hepatol 40: 660–8

    Article  CAS  PubMed  Google Scholar 

  191. Rapaccini GL, Pompili M, Caturelli E, et al (2004) Hepatocellular carcinomas < 2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int 24: 124–130

    Article  PubMed  Google Scholar 

  192. Reynaert H, Rombouts K, Vandermonde A, et al (2004) Expression of somatostatin receptors in normal and cir-rhotic human liver and in hepatocellular carcinoma. Gut 53: 1180–9

    Article  CAS  PubMed  Google Scholar 

  193. Ribes J, Clèries R, Esteban L, et al (2008) The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 49: 233–42

    Article  CAS  PubMed  Google Scholar 

  194. Roberts LR, Gores GJ (2005) Hepatocellular carcinoma: molecular pathways, and new therapeutic targets. Semin Liver Dis 25: 212–25

    Article  CAS  PubMed  Google Scholar 

  195. Saar B, Kellner-Weldon F (2008) Radiological diagnosis of hepatocellular carcinoma. Liver Intern 28: 189–99

    Article  CAS  Google Scholar 

  196. Sala M, Llovet JM, Vilana R, et al (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40: 1352–60

    Article  PubMed  Google Scholar 

  197. Sangiovanni A, Del Ninno E, Fasani P, et al (2004) Increased survival of cirrhotic patients with a hepatocel-lular carcinoma detected during surveillance. Gastro-enterology 126: 1005–14

    Article  Google Scholar 

  198. Satyanarayana A, Manns MP, Rudolph L (2004) Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 40: 276–83

    Article  CAS  PubMed  Google Scholar 

  199. Sato Y, Kato J, Takimoto R, et al (2006) Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor expression via activation of nuclear factor-κB. Gut 55: 1801–8

    Article  CAS  PubMed  Google Scholar 

  200. Schafer DF, Sorrell MF (1999) Hepatocellular carcinoma. Lancet 353: 1253–7

    Article  CAS  PubMed  Google Scholar 

  201. Schlaeger C, Longerich T, Schiller C, et al (2008) Etiology-dependent molecular mechanisms in human hepatocar-cinogenesis. Hepatology 47: 511–20

    Article  CAS  PubMed  Google Scholar 

  202. Schwegler EE, Cazares L, Steel LF, et al (2005) SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41: 634–42

    Article  PubMed  Google Scholar 

  203. Seimiya M, Tomonaga T, Matsushita K, et al (2008) Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepa-tology 48: 519–30

    CAS  Google Scholar 

  204. Sell S (2001) Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 33: 738–50

    Article  CAS  PubMed  Google Scholar 

  205. Semela D, Dufour JF (2004) Angiogenesis and hepatocel-lular carcinoma. J Hepatol 41: 864–80

    Article  PubMed  Google Scholar 

  206. Shah TU, Semelka RC, Pamuklar E, et al (2006) The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am J Gastroenterol 101: 533–540

    Article  PubMed  Google Scholar 

  207. Sherman M, Peltekian KM, Lee C (1995) Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 22: 432–8

    CAS  PubMed  Google Scholar 

  208. Sherman M (2004) Pathogenesis and screening for hepato-cellular carcinoma. Clin Liv Dis 8: 419–43

    Article  Google Scholar 

  209. Shiina S, Teratani T, Obi S, et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122–30

    Article  PubMed  Google Scholar 

  210. Shiomi S, Nishiguchi S, Ishizu H, et al (2001) Usefulness of positron emission tomography with fluorine-18-fluoro-deoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96: 1877–80

    Article  CAS  PubMed  Google Scholar 

  211. Shupe T, Petersen BE (2005) Evidence regarding a stem cell origin of hepatocellular carcinoma. Stem Cell Rev 1: 261–4

    Article  CAS  PubMed  Google Scholar 

  212. Silva MA, Hegab B, Hyde C, et al (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57: 1592–6

    Article  CAS  PubMed  Google Scholar 

  213. Simson IM (1982) Membranous obstruction of the inferior vena cava and hepatocellular carcinoma in South Africa. Gastroenterology 82: 171–8

    CAS  PubMed  Google Scholar 

  214. Sorensen JB, Klee M, Palshof T (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67: 773–5

    CAS  Google Scholar 

  215. Spangenberg HC (2007) Lokal-ablative Therapie. Der Gastroenterologe 2: 27–33

    Article  Google Scholar 

  216. Strey CW, Zapletal C, Bechstein OW (2007) Chirurgische Therapie des hepatozellulären Karzinoms. Der Gastro-enterologe 2: 20–6

    Article  Google Scholar 

  217. Szmuness W (1978) Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 24: 40–69

    CAS  PubMed  Google Scholar 

  218. Takamori R, Wong LL, Dang C, et al (2000) Needle-tract implantation from hepatocellular cancer: is needle biopsy always necessary? Liver Transpl 6: 67–72

    CAS  PubMed  Google Scholar 

  219. Takayama T, Makuuchi M, Hirohashi S, et al (1998) Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28: 1241–6

    Article  CAS  PubMed  Google Scholar 

  220. Takayasu K, Arii S, Ikai I, et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastro-enterology 131: 461–9

    Article  CAS  Google Scholar 

  221. Takeda Y, Togashi H, Shinzawa H, et al (2000) Case report: spontaneous regression of hepatocellular carcinoma and review of the literature. J Gastroenterol Hepatol 15: 1079–86

    Article  CAS  PubMed  Google Scholar 

  222. Talwalkar JA, Gores GJ (2004) Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 127: S126–32

    Article  PubMed  Google Scholar 

  223. Tanabe KK, Lemoine A, Finkelstein DM, et al (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299: 53–60

    Article  CAS  PubMed  Google Scholar 

  224. Tannapfel A, Wittekind C (2001) Präneoplasien der Leber. Definition, Differenzialdiagnose, klinische Konsequenz. Pathologe 22: 399–406

    Article  CAS  PubMed  Google Scholar 

  225. Tateishi R, Yoshida H, Shiina S, et al (2005) Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 54: 419–25

    Article  CAS  PubMed  Google Scholar 

  226. Tateishi R, Shiina S, Yoshida H, et al (2006) Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44: 1518–27

    Article  CAS  PubMed  Google Scholar 

  227. Taura N, Hamasaki K, Nakao K, et al (2006) The impact of newer treatment modalities on survival in patients with hepa-tocellular carcinoma. Clin Gastroenterol Hepatol 4: 1177–83

    Article  PubMed  Google Scholar 

  228. The Cancer of the Liver Italian Program (CLIP) Investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28: 751–5

    Article  Google Scholar 

  229. The Cancer of the Liver Italian Program (CLIP) Investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31: 840–5

    Article  Google Scholar 

  230. Thorgeirsson SS, Lee JS, Grisham JW (2006) Molecular prognostication of liver cancer: end of the beginning. J Hepatol 44: 798–805

    Article  CAS  PubMed  Google Scholar 

  231. Torimura T, Ueno T, Kin M, et al (2004) Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 40: 799–807

    Article  CAS  PubMed  Google Scholar 

  232. Toyoda H, Kumada T, Kiriyama S, et al (2005) Comparison of the usefulness of three staging systems for hepatocellu-lar carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 100: 1764–71

    Article  PubMed  Google Scholar 

  233. Toyoda H, Kumada T, Kiriyama S, et al (2006) Impact of surveillance on survival of patients with initial hepatocel-lular carcinoma: a study from Japan. Clin Gastroenterol Hepatol 4: 1170–6

    Article  PubMed  Google Scholar 

  234. Toyoda H, Kumada T, Kaneoka Y, et al (2008) Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients. J Hepatol 48: 43–50

    Article  CAS  PubMed  Google Scholar 

  235. Toyoda H, Kumada T, Kaneoka Y, et al (2008) Prognostic value of pretreatment levels of tumor markers for hepato-cellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 49: 223–32

    Article  CAS  PubMed  Google Scholar 

  236. Trevisani F, Cantarini MC, Labate AM, et al (2004) Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 99: 1470–6

    Article  PubMed  Google Scholar 

  237. Tseng CS, Tang KS, Lo HW, et al (2005) UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol 100: 1758–63

    Article  CAS  PubMed  Google Scholar 

  238. Ueno S, Tanabe G, Sako K, et al (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 34: 529–34

    Article  CAS  PubMed  Google Scholar 

  239. Velázquez RF, Rodríguez M, Navascués CA, et al (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37: 520–7

    Article  PubMed  Google Scholar 

  240. Veldt BJ, Chen W, Heathcote EJ, et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47: 1856–62

    Article  PubMed  Google Scholar 

  241. Vona G, Estepa L, Béroud C, et al (2004) Impact of cyto-morphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39: 792–7

    Article  PubMed  Google Scholar 

  242. Wada Y, Nakashima O, Kutami R, et al (1998) Clinico-pathological study on hepatocellular carcinoma with lym-phocytic infiltration. Hepatology 27: 407–14

    Article  CAS  PubMed  Google Scholar 

  243. Watanabe S, Okita K, Harada T, et al (1983) Morphologic studies of the liver cell dysplasia. Cancer 51: 2197–205

    Article  CAS  PubMed  Google Scholar 

  244. Weinberg AG, Mize CE, Worthan HG (1976) The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Prdiatr 88: 434–8

    Article  CAS  Google Scholar 

  245. Wong CM, Ng YL, Lee JM, et al (2007) Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45: 1129–38

    Article  CAS  PubMed  Google Scholar 

  246. Wong DK, Yuen MF, Poon RT, et al (2006) Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 45: 553–9

    Article  CAS  PubMed  Google Scholar 

  247. Wong GL, Wong VW, Tan GM, et al (2008) Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 28: 79–87

    Article  CAS  PubMed  Google Scholar 

  248. Wun YT, Dickinson JA, Wun YT, et al (2004) Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B (Cochrane Review). In: The Cochrane Library, Issue 3. Wiley, Chichester

    Google Scholar 

  249. Yagmur E, Rizk M, Stanzel S, et al (2007) Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol 19: 755–61

    Article  CAS  PubMed  Google Scholar 

  250. Yang HI, Lu SN, Liaw YF, et al (2002) Hepatitis Be antigens and the risk of hepatocellular carcinoma. N Engl J Med 347: 168–74

    Article  CAS  PubMed  Google Scholar 

  251. Yao FY (2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transpl 8: 1982–9

    Article  CAS  Google Scholar 

  252. Yao F Y, Kerlan RK Jr, Hirose R, et al (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48: 819–27

    Article  PubMed  Google Scholar 

  253. Yeo W, Mo FK, Chan SL, et al (2007) Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 45: 1382–9

    Article  CAS  PubMed  Google Scholar 

  254. Yeung YP, Lo CM, Liu CL, et al (2005) Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100: 1995–2004

    Article  PubMed  Google Scholar 

  255. Yuan JM, Govindarajan S, Arakawa K, et al (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 101: 1009–17

    Article  PubMed  Google Scholar 

  256. Yuen MF, Cheng CC, Lauder IJ, et al (2000) Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 31: 330–5

    Article  CAS  PubMed  Google Scholar 

  257. Yuen MF, Poon RTP, Lai CL, et al (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepa-tology 36: 687–91

    CAS  Google Scholar 

  258. Zavaglia C, De Carlis L, Alberti AB, et al (2005) Predictors of long-term survival after liver transplantation for hepato-cellular carcinoma. Am J Gastroenterol 100: 2708–16

    Article  PubMed  Google Scholar 

  259. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417–22

    PubMed  Google Scholar 

References

  1. Berman MA, Burnham JA, Sheahan DG (1988) Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 19: 784–94

    Article  CAS  PubMed  Google Scholar 

  2. Craig JR, Peters RL, Edmondson HA, et al (1980) Fibro-lamellar carcinoma of the liver. A tumor of adolescents and young adults with distinctive clinico-pathological features. Cancer 46: 372–9

    Article  CAS  PubMed  Google Scholar 

  3. El-Serag HB, Davila J (2004) Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 39: 798–803

    Article  PubMed  Google Scholar 

  4. Houben KE, McCall JL (1999) Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg 5: 91–5

    Article  CAS  PubMed  Google Scholar 

  5. Pinna AD, Iwatsuki S, Lee RG, et al (1997) Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 26: 877–83

    Article  CAS  PubMed  Google Scholar 

  6. Ringe B, Wittekind C, Weimann A, et al (1992) Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 175: 299–305

    CAS  PubMed  Google Scholar 

  7. Ruffin MT (1990) Fibrolamellar hepatoma. Am J Gastroenterol 85: 577–81

    PubMed  Google Scholar 

  8. Sirivatanauksorn Y, Sirivatanauksorn V, Lemoine NR, et al (2001) Genomic homogeneity in fibrolamellar carcinomas. Gut 49: 82–6

    Article  CAS  PubMed  Google Scholar 

  9. Sorelde O, Czemiak A, Bradpiece H, et al (1986) Characteristics of fibrolamellar hepatocellular carcinoma: a study of nine cases and a review of the literature. Am J Surg 151: 518–23

    Article  Google Scholar 

References

  1. Conran RM, Hitchcock CL, Waclawiw MA, et al (1992) Hepatoblastoma: the prognostic significance of histologic type. Pediatr Pathol 12: 167–83

    Article  CAS  PubMed  Google Scholar 

  2. Ishak KG, Glunz PR (1967) Hepatoblastoma and hepatocar-cinoma in infancy and childhood. Cancer 20: 396–422

    Article  CAS  PubMed  Google Scholar 

  3. Koneru B, Flye MW, Busuttil RW, et al (1991) Liver transplantation for hepatoblastoma. The American experience. Ann Surg 213: 118–21

    Article  CAS  PubMed  Google Scholar 

  4. Stocker JT (1990) Hepatic tumours. In: Balistreri WF, Stocker JT (eds) Paediatric hepatology. Hemisphere, New York, pp 399–488

    Google Scholar 

  5. Van Eyken P, Sciot R, Callea F, et al (1990) A cytokeratin-immunohistochemical study of hepatoblastoma. Hum Pathol 21: 302–8

    Article  PubMed  Google Scholar 

  6. Weinberg AG, Finegold MJ (1983) Primary hepatic tumors of childhood. Hum Pathol 14: 512–37

    Article  CAS  PubMed  Google Scholar 

  7. Wittekind C, Tannapfel A (2000) Tumoren der Leber. In: Denk H, Dienes HP, Düllmann J, et al (eds) Pathologie der Leber und Gallenwege. Springer Verlag, Berlin/ Heidelberg/New York/Tokyo, pp 871–939

    Google Scholar 

References

  1. Alrenga DP (1975) Primary angiosarcoma of the liver. Int Surg 60: 198–203

    CAS  PubMed  Google Scholar 

  2. Awan S, Davenport M, Portmann B, et al (1996) Angiosar-coma of the liver in children. Pediatr Surg 31: 1729–32

    Article  CAS  Google Scholar 

  3. Bioulac-Sage P, Laumonier H, Laurent C, et al (2008) Benign an malignant vascular tumors of the liver in adults. Semin Liver Dis 28: 302–14

    Article  PubMed  Google Scholar 

  4. Buetow PC, Buck JL, Ros PR, et al (1994) Malignant vascular tumors of the liver. Radiologic-pathologic correlation. From the archives of the AFIP. Radiographics 14: 153–66

    CAS  PubMed  Google Scholar 

  5. Creech JL Jr, Johnson MN (1974) Angiosarcoma of the liver in the manufacture of polyvinyl chloride. J Occup Mad 16: 150–1

    Google Scholar 

  6. Guarda LA, Ordonez NG, Smith LG Jr, et al (1982) Immu-noperoxidase localization of factor VIII in angiosarcomas. Arch Pathol Lab Med 106: 515–6

    CAS  PubMed  Google Scholar 

  7. Ishak KG (1976) Malignant mesenchymal tumors of the liver. In: Okuda K, Peters RL (eds) Hepatocellular carcinoma. Wiley, New York, pp 247–307

    Google Scholar 

  8. Ito Y, Kojiro M, Nakashima T, et al (1988) Pathomorphologic characteristics of 102 cases of Thorotrast-related hepatocel-lular carcinoma, cholangiocarcinoma, and hepatic angiosar-coma. Cancer 62: 1153–62

    Article  CAS  PubMed  Google Scholar 

  9. Kasper ML, Schonfield L, Strom RL, et al (1984) Hepatic angiosarcoma and bronchioloalveolar carcinoma induced by Fowler's solution. JAMA 252: 3407–8

    Article  CAS  PubMed  Google Scholar 

  10. Levy DW, Rindsberg S, Friedman AC, et al (1986) Thorotrast-induced hepatosplenic neoplasia: CT identification. Am J Roentgenol 146: 997–04

    CAS  Google Scholar 

  11. Lincoln DT, Singal PK, Al-Banaw A (2007) Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Anticancer Res 27: 4201–18

    CAS  PubMed  Google Scholar 

  12. Locker GY, Doroshow JH, Zwelling LA, et al (1979) The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore) 58: 48–64

    Article  CAS  Google Scholar 

  13. MacMohan HE, Murphy AS, Bates MI (1947) Endothelial cell sarcoma of liver following thorotrast injections. Am J Pathol 23: 585–611

    Google Scholar 

  14. Maluf D, Cotterell A, Clark B (2005) Hepatic angiosarcoma and liver transplantation: case report and literature review. Transpl Proc 237: 2195–9

    Article  Google Scholar 

  15. Mani H, van Thiel DH (2001) Mesenchymal tumors of the liver. Clin Liv Dis 5: 219–57

    Article  CAS  Google Scholar 

  16. Regelson W, Kim U, Ospina J, et al (1968) Heman-gioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer 21: 514–22

    Article  CAS  PubMed  Google Scholar 

  17. Soini Y, Welsh JA, Ishak KG, et al (1995) p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis 16: 2879–81

    Article  CAS  PubMed  Google Scholar 

  18. van Kampen RJ, Erdkamp FL, Peters FP (2007) Thorium dioxide-related haemangiosarcoma of the liver. Neth J Med 65: 279–82

    PubMed  Google Scholar 

References

  1. Bioulac-Sage P, Laumonier H, Laurent C, et al (2008) Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis 28: 302–14

    Article  PubMed  Google Scholar 

  2. Demetris AJ, Minervini M, Raikow RB, et al (1997) Hepatic epithelioid hemangioendothelioma. Am J Surg Pathol 21: 263–70

    Article  CAS  PubMed  Google Scholar 

  3. Ishak KG, Sesterhenn IA, Goodman ZD, et al (1984) Epithelioid hemangioendothelioma of the liver: a clinico-pathologic and follow-up study of 32 cases. Hum Pathol 15: 839–52

    Article  CAS  PubMed  Google Scholar 

  4. Läuffer JM, Zimmermann A, Krähenbühl L, et al (1996) Epithelioid hemagioendothelioma of the liver. A rare hepatic tumor. Cancer 78: 2318–27

    Article  PubMed  Google Scholar 

  5. Makhlouf HR, Ishak KG, Goodman ZD (1999) Epithelioid hemangioendothelioma of the liver. A clinicopathologic study of 137 cases. Cancer 85: 562–82

    Article  CAS  PubMed  Google Scholar 

  6. Mehrabi A, Kashfi A, Fonouni H, et al (2006) Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 107: 2108–21

    Article  PubMed  Google Scholar 

  7. Taege C, Holzhausen HJ, Günter G, et al (1999) Das maligne epitheloide Hämangioendotheliom der Leber. Ein sehr seltener Tumor im Kindesalter. Pathologe 20: 345–50

    Article  CAS  PubMed  Google Scholar 

  8. Walsh MW, Hytiroglou P, Thung SN, et al (1998) Epithelioid hemangioendothelioma of the liver mimicking Budd-Chiari syndrome. Arch Pathol Lab Med 122: 846–8

    CAS  PubMed  Google Scholar 

  9. Weiss SW, Enzinger FM (1982) Epithelioid hemangioen-dothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 50: 970–81

    Article  CAS  PubMed  Google Scholar 

References

  1. Lauwers GY, Grant LD, Donnelly WH, et al (1997) Hepatic undifferentiated (embryonal) sarcoma arising in a mesen-chymal hamartoma. Am J Surg Pathol 21: 1248–54

    Article  CAS  PubMed  Google Scholar 

  2. Leuschner I, Schmidt D, Harms D (1990) Undifferentiated sarcoma of the liver in childhood: morphology, flow cytom-etry and literature review. Hum Pathol 21: 68–76

    Article  CAS  PubMed  Google Scholar 

  3. Perilongo G, Carli M, Sainati L, et al (1987) Undifferentiated (embryonal) sarcoma of the liver in childhood: results of a retrospective Italian study. Tumori 73: 213–7

    CAS  PubMed  Google Scholar 

  4. Stocker JT, Ishak KG (1978) Undifferentiated (embryonal) sarcoma of the liver. Report of 31 cases. Cancer 42: 336–48

    Article  CAS  PubMed  Google Scholar 

  5. Walker NI, Horn MJ, Storn RW, et al (1992) Undifferentiated (embryonal) sarcoma of the liver. Pathologic findings and long-term survival after complete surgical resection. Cancer 69: 52–9

    Article  CAS  PubMed  Google Scholar 

  6. Webber EM, Morrison KB, Pritchard SL, et al (1999) Undifferentiated embryonal sarcoma of the liver: results of clinical management in one center. J Pediatr Surg 34: 1641–4

    Article  CAS  PubMed  Google Scholar 

  7. Zheng JM, Tao X, Xu AM, et al (2007) Primary and recurrent embryonal sarcoma of the liver: clinicopathological and immunohistochemical analysis. Histopathology 51: 195–203

    Article  PubMed  Google Scholar 

References

  1. Anthony PP, Sarsfield P, Clarke T (1990) Primary lymphoma of the liver: clinical ad pathological features of 10 patients. J Clin Pathol 43: 1007–13

    Article  CAS  PubMed  Google Scholar 

  2. Appelbaum L, Lederman R, Agid R, et al (2005) Hepatic lymphoma: an imaging approach with emphasis on image-guided needle biopsy. Isr Med Assoc J 7: 19–22

    PubMed  Google Scholar 

  3. Ata AA, Kamal IA (1965) Primary reticulum cell sarcoma of the liver: a case report. J Egypt Med Assoc 48: 514–21

    CAS  PubMed  Google Scholar 

  4. Avlonitis VS, Linos D (1999) Primary hepatic lymphoma: a review. Eur J Surg 165: 725–9

    Article  CAS  PubMed  Google Scholar 

  5. Bangerter M, Moog F, Griesshammer M, et al (1997) Usefulness of FDG-PET in diagnosing primary lymphoma of the liver. Int J Hematol 66: 517–20

    Article  CAS  PubMed  Google Scholar 

  6. Baschinsky DY, Weidner N, Baker PB, et al (2001) Primary hepatic anaplastic large-cell lymphoma of T-cell phenotype in acquired immunodeficiency syndrome: a report of an autopsy case and review of the literature. Am J Gastroenterol 96: 227–32

    Article  CAS  PubMed  Google Scholar 

  7. Chowla A, Malhi-Chowla N, Chidambaram A, et al (1999) Primary hepatic lymphoma in hepatitis C: case report and review of the literature. Ann Surg 65: 881–3

    CAS  Google Scholar 

  8. De Ment SH, Mann RB, Staal SP, et al (1987) Primary lym-phomas of the liver. Report of six cases and review of the literature. Am J Clin Pathol 88: 255–63

    Google Scholar 

  9. De Renzo A, Perna F, Persico M, et al (2008) Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma. Eur J Haematol 81: 51–7

    Article  PubMed  Google Scholar 

  10. Gaulard P, Zafrani ES, Mavier P, et al (1986) Peripheral T-cell lymphoma presenting as predominant liver disease: a report of three cases. Hepatology 6: 864–8

    Article  CAS  PubMed  Google Scholar 

  11. Koubaa Mahjoub W, Chaumette-Planckaert MT, Penas EM, et al (2008) Primary hepatic lymphoma of mucosa-associ-ated lymphoid tissue type: a case report with cytogenetic study. Int J Pathol 16: 301–7

    Article  Google Scholar 

  12. Maes M, Depardieu C, Dargent JL, et al (1997) Primary low-grade B-cell lymphoma of MALT-type occurring in the liver: a study of two cases. J Hepatol 27: 922–7

    Article  CAS  PubMed  Google Scholar 

  13. Nagano K, Fukuda Y, Nakano I, et al (1999) Case report: reactive lymphoid hyperplasia of liver coexisting with chronic thyroiditis: radiographical characteristics of the disorder. J Gastroenterol Hepatol 14: 163–7

    Article  CAS  PubMed  Google Scholar 

  14. Nieters A, Kallinowski B, Brennan P, et al (2006) Hepatitis C and risk of lymphoma: results of the European Multicenter Case-Control Study EPILYMPH. Gastroenterology 131: 1879–86

    Article  CAS  PubMed  Google Scholar 

  15. Prabhu BM, Medeiros J, Kumar D, et al (1998) Primary hepatic low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) associated with primary biliary cirrhosis. Mod Pathol 11: 404–10

    CAS  PubMed  Google Scholar 

  16. Sato S, Masuda T, Oikawa H, et al (1999) Primary hepatic lymphoma associated with primary biliary cirrhosis. Am J Gastroenterol 94: 1669–73

    Article  CAS  PubMed  Google Scholar 

  17. Scerpella EG, Villareal AA, Casanova PF, et al (1996) Primary lymphoma of the liver in AIDS: report of a new case and review of the literature. J Clin Gastroenterol 22: 51–3

    Article  CAS  PubMed  Google Scholar 

  18. Wohlfarth A, Wohlfarth M, Rieβ R, et al (1999) Das primäre extranodale Non-Hodgkin-Lymphom der Leber. Leber Magen Darm 29: 42–4

    Google Scholar 

  19. Yokomori H, Kaneko F, Sato A, et al (2008) Primary hepatic presentation of Hodgkin's lymphoma: a case report. Hepatol Res 38: 1054–7

    Article  PubMed  Google Scholar 

  20. Zafrani ES, Gaulard P (1993) Primary lymphoma of the liver. Liver 13: 57–61

    CAS  PubMed  Google Scholar 

References

  1. Al-Agha OM, Igbowke AA (2008) Malignant fibrous histio-cytoma: between past and present. Arch Pathol Lab Med 132: 1030–5

    PubMed  Google Scholar 

  2. Alberti-Flor JJ, O'Hara MF, Weaver F, et al (1985) Malignant fibrous histiocytoma of the liver. Gastroenterology 89: 890–3

    CAS  PubMed  Google Scholar 

  3. Pathol Int 225–9

    Google Scholar 

  4. Fukuyama M, Koike M (1986) Malignant fibrous histiocy-toma arising in the liver. Arch Pathol Lab Med 110: 203–6

    Google Scholar 

  5. Li YR, Akbari E, Tretiakova MS, et al (2008) Primary hepatic malignant fibrous histiocytoma: clinicopathologic characteristics and prognostic value of ezrin expression. Am J Surg Pathol 32: 1144–58

    Article  PubMed  Google Scholar 

  6. Schweyer S, Meyer-Venter R, Lorf T, et al (2000) Malignes fibröses Histiozytom der Leber. Z Gastroenterol 38: 243–8

    Article  CAS  PubMed  Google Scholar 

  7. Bioulac-Sage P, Laumonier H, Laurent C, et al (2008) Benign an malignant vascular tumors of the liver in adults. Semin Liver Dis 28: 302–14

    Article  PubMed  Google Scholar 

  8. Ioachim HL, Adsay V, Giancotti FR, et al (1995) Kaposi's sarcoma of internal organs. Cancer 75: 1376–85

    Article  CAS  PubMed  Google Scholar 

  9. Weninger W, Partanen TA, Breiteneder-Geleff S (1999) Expression of vascular endothelial growth factor and podo-planin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 79: 243–51

    CAS  PubMed  Google Scholar 

  10. Mani H, van Thiel DH (2001) Mesenchymal tumours of the liver. Clin Liv Dis 5: 219–57

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair, Department of Medicine II, Klinikum Offenbach, Goethe University Frankfurt/Main, Starkenburgring 66, Offenbach, 63069, Germany

    Henryk Dancygier (Professor of Medicine)

  2. Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA

    Henryk Dancygier (Professor of Medicine)

Authors
  1. Henryk Dancygier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dancygier, H. (2010). Malignant Tumors. In: Clinical Hepatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04519-6_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04519-6_48

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04509-7

  • Online ISBN: 978-3-642-04519-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation